In the present study, to directly test the impact of F311I/T315I-BCR::ABL1 on TKI sensitivities in a human Ph+ leukemia model, we tried to introduce either the solo mutation of F311I or T315I, or the compound mutation of F311I/T315I, into the intrinsic BCR::ABL1 gene of the human Ph+ myeloid leukemia cell line by applying the homologous recombination (HR) of three corresponding templates using the CRISPR/Cas9 system. This evidence concerns the gene ABL1 and myeloid leukemia.